Pharmacy Service of Clinical Center, Chemnitz, Germany.
Center for Evidence-based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
Pharmacoepidemiol Drug Saf. 2020 Mar;29(3):229-251. doi: 10.1002/pds.4968. Epub 2020 Feb 11.
The need for drug-related safety warnings is undisputed, and their impact should also be evaluated. This systematic review investigates and assesses the impact of safety warnings on drug therapy.
Studies published in English between January 1998 and December 2018 were searched in EMBASE and MEDLINE, complemented by manual search. Randomised controlled trials, cohort studies with a before/after component, and case-control studies were included, selected to predefined criteria, and assessed for their reporting and methodological quality.
Out of 7454 references identified, 72 studies were included. A total of 28/72 (39%) studies described the impact of safety warnings on drug therapy as being effective, whereas 12/72 (17%) studies did not. Further, 26/72 (36%) studies described a partial implementation of the warnings (one part of the warning had an impact on drug therapy and another did not). Unintended effects were investigated in 6/72 (8%) studies. While 34 (47%) studies examined safety warnings on psychotropic drugs using an interrupted time series (ITS) design (53%), a before/after (26%), and a time series design (21%), 38 (53%) studied other substances using an ITS design (34%), a before/after (40%), and a time series design (26%). The proportion of an effective impact on drug therapy was lower in the "psychotropic drugs" group (23%) than in the "others" group (53%).
Drug-related safety warnings induce intended and unintended effects. The included studies are of broadly varying methodological quality. To better compare their effectiveness, studies should be conducted using standardised procedures.
药物相关安全性警示的必要性毋庸置疑,其影响也应加以评估。本系统评价旨在调查和评估安全性警示对药物治疗的影响。
检索 1998 年 1 月至 2018 年 12 月期间在 EMBASE 和 MEDLINE 上发表的英文文献,并辅以手工检索。纳入符合预设标准的随机对照试验、具有前后对照部分的队列研究和病例对照研究,并对其报告和方法学质量进行评估。
在 7454 篇参考文献中,有 72 篇符合纳入标准。共 28/72(39%)项研究描述安全性警示对药物治疗的影响是有效的,而 12/72(17%)项研究则认为无效。此外,26/72(36%)项研究描述了警示措施的部分实施(警示的一部分对药物治疗有影响,而另一部分则没有)。有 6/72(8%)项研究调查了意外影响。虽然有 34(47%)项研究使用中断时间序列(ITS)设计(53%)、前后设计(26%)和时间序列设计(21%)来研究精神药物的安全性警示,但有 38(53%)项研究使用 ITS 设计(34%)、前后设计(40%)和时间序列设计(26%)来研究其他物质的安全性警示。对药物治疗有有效影响的比例在“精神药物”组(23%)低于“其他”组(53%)。
药物相关安全性警示会产生预期和非预期的影响。纳入的研究方法学质量差异较大。为了更好地比较其有效性,应使用标准化程序进行研究。